An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Professor Dr. Bernd Mühlbauer
With
Institut National de la Santé Et de la Recherche Médicale, France
World Health Organization
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients 18 years and older
Current SARS-CoV-2 infection
Admitted to the hospital ward or the ICU due to COVID-19
SpO2 \<= 94% on room air OR oxygen demand OR breathing support
Written informed consent obtained
You may not be if
Patient's non-consent or inability to informed consent
Pregnant or breastfeeding women.
Subjects pretreated with one of the study drugs in the past 29 days
Anticipated transfer within 72 hours to a non-study hospital
Severe co-morbidity with life expectancy \< 3 months
AST or ALT \> 5 times the upper limit of normal
Stage 4 severe chronic kidney disease or requiring dialysis
Contraindications and known intolerance to any of the study drugs
Subjects participating in a potentially confounding drug or device trial
Any reason why the patient should not participate (investigator's opinion)
Clareo Health | An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
